Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/75699
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJutatip Kaewmaleeen_US
dc.contributor.authorAtcharaporn Ontawongen_US
dc.contributor.authorAcharaporn Duangjaien_US
dc.contributor.authorChittreeya Tansakulen_US
dc.contributor.authorVatcharin Rukachaisirikulen_US
dc.contributor.authorChatchai Muanprasaten_US
dc.contributor.authorChutima Srimaroengen_US
dc.date.accessioned2022-10-16T07:01:58Z-
dc.date.available2022-10-16T07:01:58Z-
dc.date.issued2021-04-01en_US
dc.identifier.issn14248247en_US
dc.identifier.other2-s2.0-85104935465en_US
dc.identifier.other10.3390/ph14040375en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85104935465&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/75699-
dc.description.abstractIsolated α,β-dehydromonacolin S (C5) from soil-derived fungus Aspergillus sclerotiorum PSU-RSPG178 was recently shown to exhibit an inhibitory effect against 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in vitro. In this study, we investigated the effects of C5 on lipid-lowering, hepatic steatosis, and hepatic gluconeogenesis in vivo. The control rats received a daily dose of either vehicle or C5 at 10 mg/kg, while the high-fat diet-induced obese (HFD) rats were administered vehicle; 1, 3, or 10 mg/kg C5; or 10 mg/kg lovastatin (LO) for 6 weeks. C5 significantly improved dyslipidemia and diminished liver enzymes, HMGR activity, insulin resistance, and hepatic steatosis, comparable to LO without any hepatotoxicity and nephrotoxicity in HFD rats. A higher efficacy of C5 in lipid-lowering activity and anti-hepatic steatosis was associated with a significant decrease in genes involved in lipid metabolism including sterol regulatory element binding protein (SREBP) 1c, SREBP2, liver X receptor alpha (LXRα), and peroxisome proliferator-activated receptor (PPAR) gamma (PPARγ) together with an increase in the PPAR alpha (PPARα). Correspondingly, C5 was able to down-regulate the lipid transporters cluster of differentiation 36 (CD36) and Niemann-Pick C1 Like 1 (NPC1L1), increase the antioxidant superoxide dismutase gene expression, and decrease the proinflammatory cytokines, tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1β). Impairment of hepatic gluconeogenesis and insulin resistance in HFD rats was restored by C5 through down-regulation of the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and the activation of AMP-dependent kinase serine (AMPK) and serine/threonine protein kinase B (Akt). Collectively, this novel C5 may be a therapeutic option for treating dyslipidemia, hepatic steatosis, and reducing potential risk for diabetes mellitus.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleHigh-efficacy α,β-dehydromonacolin s improves hepatic steatosis and suppresses gluconeogenesis pathway in high-fat diet-induced obese ratsen_US
dc.typeJournalen_US
article.title.sourcetitlePharmaceuticalsen_US
article.volume14en_US
article.stream.affiliationsUniversity of Phayaoen_US
article.stream.affiliationsFaculty of Medicine Ramathibodi Hospital, Mahidol Universityen_US
article.stream.affiliationsPrince of Songkla Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.